Literature DB >> 25785160

Arsenical keratosis caused by medication: a case report and literature.

Sijing Zhou1, Junsheng Zhou2, Shengping Liu2, Ran Wang3, Zaixing Wang4.   

Abstract

Medication-induced arsenical keratosis is a rare type of arsenical keratosis. We describe here a case of 70-year-old man to explore the clinical characters, diagnosis and treatment of medication-induced arsenical keratosis in order to improve the understanding of this disease and reduce the misdiagnosis rate. The clinical characters, signs, lab findings as well as progression, diagnosis and treatment in the case of arsenical keratosis were analyzed. The patient of medication-induced arsenical keratosis suffered from chronic eczema. He has taken realgar during the treatment. His medication caused arsenical keratosis. Medication-induced arsenical keratosis is rare. Making the medication history clear and using urine arsenic detection if necessary are of significance to understand the patients' condition. It is quite effective that using Sodium Dimercaptosulphonate during the treatment without delay.

Entities:  

Keywords:  Herbal medication-induced; arsenic trioxide; arsenical keratosis

Year:  2015        PMID: 25785160      PMCID: PMC4358615     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  16 in total

1.  Preventive effects of taurine and vitamin C on renal DNA damage of mice exposed to arsenic.

Authors:  Zongyuan Li; Fengyuan Piao; Shuang Liu; Lin Shen; Ning Sun; Bin Li; Shuxian Qu
Journal:  J Occup Health       Date:  2009-02-03       Impact factor: 2.708

2.  Overabundance of putative cancer stem cells in human skin keratinocyte cells malignantly transformed by arsenic.

Authors:  Yang Sun; Erik J Tokar; Michael P Waalkes
Journal:  Toxicol Sci       Date:  2011-10-19       Impact factor: 4.849

Review 3.  Selenium interactions and toxicity: a review. Selenium interactions and toxicity.

Authors:  Iwona Zwolak; Halina Zaporowska
Journal:  Cell Biol Toxicol       Date:  2011-09-14       Impact factor: 6.691

4.  Lung cancer and arsenic concentrations in drinking water in Chile.

Authors:  C Ferreccio; C González; V Milosavjlevic; G Marshall; A M Sancha; A H Smith
Journal:  Epidemiology       Date:  2000-11       Impact factor: 4.822

5.  Mutant p53 protein is targeted by arsenic for degradation and plays a role in arsenic-mediated growth suppression.

Authors:  Wensheng Yan; Yanhong Zhang; Jin Zhang; Shou Liu; Seong Jun Cho; Xinbin Chen
Journal:  J Biol Chem       Date:  2011-03-29       Impact factor: 5.157

6.  Introduction: the history of arsenic trioxide in cancer therapy.

Authors:  K H Antman
Journal:  Oncologist       Date:  2001

Review 7.  Arsenic trioxide: an ancient drug revived.

Authors:  Jin Zhou
Journal:  Chin Med J (Engl)       Date:  2012-10       Impact factor: 2.628

8.  Tetraarsenic oxide and cisplatin induce apoptotic synergism in cervical cancer.

Authors:  Jung Mi Byun; Dae Hoon Jeong; Dae Sim Lee; Joo Ran Kim; Sae Gwang Park; Mi Seon Kang; Young Nam Kim; Kyung Bok Lee; Moon Su Sung; Ki Tae Kim
Journal:  Oncol Rep       Date:  2013-01-18       Impact factor: 3.906

9.  Chronic arsenic toxicity from Ayurvedic medicines.

Authors:  Sujay Khandpur; Amit K Malhotra; Vidhyut Bhatia; Subandhu Gupta; Vinod K Sharma; Rakesh Mishra; Narendra K Arora
Journal:  Int J Dermatol       Date:  2008-06       Impact factor: 2.736

10.  Long isoforms of NRF1 contribute to arsenic-induced antioxidant response in human keratinocytes.

Authors:  Rui Zhao; Yongyong Hou; Peng Xue; Courtney G Woods; Jingqi Fu; Bo Feng; Dawei Guan; Guifan Sun; Jefferson Y Chan; Michael P Waalkes; Melvin E Andersen; Jingbo Pi
Journal:  Environ Health Perspect       Date:  2010-08-30       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.